Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2021-09-10 Regulatory Filings
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico
Regulatory Filings Classification · 95% confidence The document is a press release dated September 10, 2021, announcing that the Mexican Patent Office granted a new patent protecting the formulation of Lactobacillus reuteri (IBP-9414). The text focuses entirely on intellectual property (patent grant) and related regulatory/legal protection (Orphan Drug Exclusivity, pending applications). This type of announcement, concerning specific legal or regulatory milestones outside of standard financial reporting (10-K, ER, IR), fits best under the 'Legal Proceedings Report' (LTR) category if it relates to litigation, or potentially 'Regulatory Filings' (RNS) as a general announcement. However, since it specifically details the expansion of intellectual property protection, which is a key legal/regulatory asset update, and does not fit the other specific categories (like M&A, Director Dealing, or Financing), it is most appropriately classified as a general Regulatory Filing (RNS) or potentially LTR if patents are grouped there. Given the options, RNS is the safest fallback for specific, non-financial regulatory news that isn't a standard report announcement. Since the document is a direct announcement of a legal/IP event, and LTR is defined as 'Updates on significant lawsuits, regulatory actions, or legal matters involving the company,' a patent grant falls under 'legal matters.' I will classify it as RNS as it is a general regulatory announcement, but LTR is a close second. Given the nature of patent grants being a form of regulatory action/legal status update, RNS (Regulatory Filings) is the most appropriate general category for non-financial, non-management specific regulatory news.
2021-09-10 English
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Mexiko.
Legal Proceedings Report Classification · 95% confidence The document is a press release dated September 10, 2021, announcing that Infant Bacterial Therapeutics AB (IBT) has been granted a new patent in Mexico for its drug candidate IBP-9414. This announcement concerns intellectual property protection and regulatory/legal developments related to a drug candidate. This fits best under 'Legal Proceedings Report' (LTR) as it relates to patent grants and intellectual property protection, which is a significant legal/regulatory event for a pharmaceutical company. It is not an earnings release (ER), a full report (10-K/IR), or a management change (MANG). Since it is a specific announcement about a legal/IP matter, LTR is the most precise fit over the general fallback RNS.
2021-09-10 Swedish
Rekryteringen av de minsta barnen i the Connection study pausad
Environmental & Social Information Classification · 99% confidence The document is titled "Pressmeddelande" (Press Release) and is dated August 25, 2021. It announces a temporary pause in recruitment for a specific clinical trial stratum ('The Connection study') pending a safety review by the Data Monitoring Committee (DMC). It also includes standard company boilerplate information and contact details. The final section states that the information is being made public according to the EU Market Abuse Regulation (MAR) and specifies the time of release. This type of announcement, which communicates material, non-public information regarding operations (like clinical trial status) to the market via a press release, fits best under the general category for regulatory announcements that aren't specific financial reports (like 10-K, ER, or IR). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback is Regulatory Filings (RNS). The document length is short (2572 chars), but it is the primary announcement itself, not an announcement *of* another report, so RPA is less suitable than RNS for this operational update.
2021-08-25 Swedish
Recruitment of the smallest infants in the Connection study paused
Legal Proceedings Report Classification · 99% confidence The document is a press release dated August 25, 2021, announcing a temporary pause in recruitment for a specific stratum (Strata A) of 'The Connection Study' pending a safety review by the Data Monitoring Committee (DMC). It discusses clinical trial progress, the company's pipeline (IBP-9414), and concludes with a statement that the information is made public pursuant to the EU Market Abuse Regulation. This type of announcement, detailing operational updates, clinical trial status, or specific corporate events that are not standard financial reports (10-K, IR, ER), typically falls under general regulatory announcements or investor relations updates. Since it is not a formal financial report, a management discussion, a dividend notice, or a director dealing report, and it is a specific, material operational update required for public disclosure, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially an Investor Presentation (IP) if it were a slide deck, but here it reads like a formal disclosure. Given the context of mandatory disclosure under EU regulations regarding clinical trial status, RNS (Regulatory Filings) is the most appropriate general category for non-standard, material announcements.
2021-08-25 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Infant Bacterial Therapeutics AB for the period of January to June 2021. It contains comprehensive financial statements, management commentary, operational updates, and risk disclosures. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-13 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January 1-June 30, 2021' and contains comprehensive financial statements, including income statements, cash flow data, and detailed management commentary on business performance, clinical trial progress, and risks. It is a formal periodic financial report for a duration shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.